Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Gross Margin (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Gross Margin for 2 consecutive years, with 80.0% as the latest value for Q2 2025.

  • On a quarterly basis, Gross Margin changed N/A to 80.0% in Q2 2025 year-over-year; TTM through Jun 2025 was 125.0%, a 2590.0% decrease, with the full-year FY2023 number at 74.26%, changed N/A from a year prior.
  • Gross Margin was 80.0% for Q2 2025 at Mereo BioPharma, down from 127.3% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 127.3% in Q4 2023 to a low of 69.6% in Q2 2023.